You are here

Catalyst Biosciences Reports Third Quarter Operating & Financial Results and Provides a Corporate Update

Presented Updated Positive Interim Data from the Phase 2/3 Study of Marzeptacog Alfa (Activated) (FVIIa) at Two Scientific Meetings

Published Data from Phase 1 Study of Marzeptacog Alfa (Activated) in the Journal of Thrombosis & Haemostasis

Ended Q3 with a cash balance of ~$129M

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced operating and financial results for the third quarter ending September 30, 2018 and provided a corporate update.

Recent Milestones:

  • Reported positive interim data from its Phase 2/3 study of subcutaneous (SQ) prophylactic Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA), being developed for the treatment of hemophilia A or B with inhibitors at the 2018 meeting of the International Society for Thrombosis & Hemostasis (ISTH) in Dublin, Ireland on July 18th and presented updated data in the Subcutaneous Delivery of Coagulation Factors session at the 2018 Hemophilia Drug Development Summit (HDDS) in Boston, MA on August 15th.
  • Published data from the Phase 1 trial of MarzAA in individuals with hemophilia A or B with or without inhibitors in the peer-reviewed Journal of Thrombosis & Haemostasis. The paper, entitled: “Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia,” described the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending intravenous (IV) bolus doses of MarzAA.
  • Initiated a comprehensive review of the Cohort 6 neutralizing antibody (nAb) observation from the Phase 1/2 study of Factor IX (FIX) variant dalcinonacog alfa (DalcA). We are planning to provide further updates on these analyses later in 2018.

“We had an active third quarter in which we presented interim data on our ongoing Phase 2/3 SQ study of MarzAA at the 2018 ISTH & HDDS meetings and published data from our Phase 1 IV trial of MarzAA in the Journal of Thrombosis & Haemostasis,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “We are very encouraged by the interim data from the Phase 2/3 study of MarzAA and plan to complete enrollment of the Phase 2 portion by the end of 2018. Simultaneously, we initiated an analysis of the nAb results from the Phase 1/2 study of dalcinonacog alfa (DalcA)(formerly CB 2679d/ISU304) Factor IX program. Our Q3 ending cash balance of $129M allows us to continue the independent development of our subcutaneous prophylactic MarzAA and DalcA candidates.”

Upcoming Milestones

  • Interim analysis from the Phase 2/3 MarzAA study at ASH 2018.
  • Additional data and analysis of the cause and impact of the antibody observations in Cohort 6 of the dalcinonacog alfa (DalcA) Phase 1/2 trial in December 2018. 

Second Quarter 2018 Results and Financial Highlights

  • Cash, cash equivalents and short-term investments, as of September 30, 2018 were $129.2 million due primarily to the approximately $106.8 million in net financing in February 2018 and $9.5 million in proceeds from the exercise of warrants during the first quarter 2018.
  • Research and development expense for the three months ended September 30, 2018 was $5.6 million, compared with $3.8 million for the prior year period. The increase was due primarily to personnel-related costs, preclinical third-party research and development service contracts and manufacturing expenses for MarzAA and DalcA.
  • General and administrative expense for the three months ended September 30, 2018 was $2.8 million compared with $2.4 million for the prior year period. The increase was due primarily to personnel related expenses and professional service costs.
  • Interest and other income for the three months ended September 30, 2018 was $0.7 million, compared with $0.1 million for the prior year period.  The increase was due primarily to investment and dividend income.
  • Net loss attributable to common stockholders for the three months ended September 30, 2018 was $7.7 million, or ($0.64) per basic and diluted share, compared with $5.8 million, or ($1.34) per basic and diluted share, for the prior year period.  
  • On February 19, 2018, the final $5 million of the company’s redeemable convertible notes matured and were repaid in full with $5 million from the company’s restricted cash. The Company has no outstanding notes or debt.
  • As of September 30, 2018, the Company had 11,942,729 shares of common stock outstanding.

About Catalyst Biosciences
Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about development plans for Catalyst’s MarzAA and DalcA, including the potential completion of the Phase 2 portion of the Phase 2/3 trial of MarzAA by the end of 2018, plans to present interim analysis from this trial at ASH 2018, plans to complete the ongoing analysis of nAbs for DalcA by December 2018, and the potential resumption of clinical trials of DalcA. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that the Company makes, including, but not limited to, the risk that trials and studies may be delayed and may not have satisfactory outcomes, that the ongoing Phase 2/3 efficacy trial may not replicate the results from earlier studies, that potential adverse effects may arise from the testing or use of MarzAA, including the generation of antibodies, that the analysis of the nAbs observed in the Phase 1/2 trial of DalcA or other factors lead us not to resume clinical trials of DalcA, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, competition and other factors that affect our ability to establish collaborations on commercially reasonable terms and other risks described in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, filed with the Securities and Exchange Commission on August 2, 2018, along with other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

Fletcher Payne, CFO
Catalyst Biosciences, Inc.

Josephine Belluardo, Ph.D.
LifeSci Public Relations

Catalyst Biosciences, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)

  September 30, 2018  December 31, 2017 
Current assets:        
Cash and cash equivalents $35,998  $14,472 
Short-term investments  93,223   17,971 
Restricted cash  50   5,333 
Prepaid and other current assets  3,538   1,333 
Total current assets  132,809   39,109 
Other assets, noncurrent  352   128 
Property and equipment, net  255   276 
Total assets $133,416  $39,513 
Liabilities and stockholders’ equity        
Current liabilities:        
Accounts payable $369  $747 
Accrued compensation  1,082   1,366 
Other accrued liabilities  1,840   1,322 
Deferred revenue     212 
Deferred rent, current portion  13   7 
Redeemable convertible notes     5,085 
Total current liabilities  3,304   8,739 
Deferred rent, noncurrent portion  161    
Total liabilities  3,465   8,739 
Stockholders’ equity:        
Preferred stock, $0.001 par value, 5,000,000 shares authorized; 0 and 3,680 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively     
Common stock, $0.001 par value, 100,000,000 shares authorized; 11,942,729 and
6,081,230 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively
  12   6 
Additional paid-in capital  322,468   204,262 
Accumulated other comprehensive income  (24)   
Accumulated deficit  (192,505)  (173,494)
Total stockholders’ equity  129,951   30,774 
Total liabilities and stockholders’ equity $133,416  $39,513 

Catalyst Biosciences, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)

  Three Months Ended September 30,  Nine Months Ended September 30, 
  2018  2017  2018  2017 
Contract revenue $  $318  $6  $700 
Operating expenses:                
Research and development  5,575   3,805   13,235   9,286 
General and administrative  2,770   2,391   8,909   7,407 
Total operating expenses  8,345   6,196   22,144   16,693 
Loss from operations  (8,345)  (5,878)  (22,138)  (15,993)
Interest and other income, net  651   85   2,920   185 
Net loss $(7,694) $(5,793) $(19,218) $(15,808)
Deemed dividend for convertible preferred stock beneficial conversion feature           (3,951)
Net loss attributable to common stockholders $(7,694) $(5,793) $(19,218) $(19,759)
Net loss per share attributable to common stockholders, basic and diluted $(0.64) $(1.34) $(1.75) $(6.49)
Shares used to compute net loss per share attributable to common stockholders, basic and diluted  11,942,729   4,310,561   10,967,750   3,043,919 


Thursday, November 1, 2018 - 08:00